← Japan catalog ← 4502 Manual 4506 → ← 4502 Pharmaceuticals 4506 →
4503 · Astellas Pharma
This is a quantitative scorecard. The numbers below are read directly from Astellas Pharma’s EDINET filing, in yen. The Japanese-language narrative, what the business does, its risks, what changed this year, is not machine-read here, so we do not paraphrase it. Find it on EDINET (code 4503) →
The record
What the business has done across the cycle, read straight from the EDINET filing: the multi-year record, and the walk from reported profit to the cash an owner could take out.
The record, 2017–2026
realized figures from each filing · older years to the left| 2017’17 | 2018’18 | 2019’19 | 2020’20 | 2021’21 | 2022’22 | 2023’23 | 2024’24 | 2025’25 | 2026’26 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| ¥1.31T | ¥1.30T | ¥1.31T | ¥1.30T | ¥1.25T | ¥1.30T | ¥1.52T | ¥1.60T | ¥1.91T | ¥2.14T | RevenueRevenue |
| — | — | — | 79% | 80% | — | — | — | 82% | 81% | Gross marginGross mgn |
| — | — | — | 38% | 40% | — | — | — | 44% | 40% | SG&A / revenueSG&A/rev |
| — | — | — | 13% | 11% | — | — | — | 9% | 8% | R&D / revenueR&D/rev |
| ¥15.6B | ¥213.3B | ¥243.9B | ¥244.0B | ¥136.1B | ¥155.7B | ¥133.0B | ¥25.5B | ¥41.0B | ¥382.6B | Operating incomeOp. inc. |
| 1.2% | 16.4% | 18.7% | 18.8% | 10.9% | 12.0% | 8.8% | 1.6% | 2.1% | 17.9% | Operating marginOp. mgn |
| ¥218.7B | ¥164.7B | ¥222.3B | ¥195.4B | ¥120.6B | ¥124.1B | ¥98.7B | ¥17.0B | ¥50.7B | ¥291.5B | Net incomeNet inc. |
| Cash flow & returns | ||||||||||
| ¥235.6B | ¥312.6B | ¥258.6B | ¥222.0B | ¥306.8B | ¥257.4B | ¥327.8B | ¥172.5B | ¥194.5B | ¥560.2B | Operating cash flowOp. cash |
| ¥16.9B | ¥147.9B | ¥36.4B | ¥26.6B | ¥186.3B | ¥133.4B | ¥229.1B | ¥155.4B | ¥143.8B | ¥268.7B | Working capital & otherWC & other |
| — | ¥25.1B | ¥25.2B | ¥41.3B | ¥31.4B | ¥30.7B | ¥36.4B | ¥38.1B | ¥37.0B | ¥57.7B | CapexCapex |
| — | 1.9% | 1.9% | 3.2% | 2.5% | 2.4% | 2.4% | 2.4% | 1.9% | 2.7% | Capex / revenueCapex/rev |
| — | ¥287.5B | ¥233.4B | ¥180.7B | ¥275.5B | ¥226.7B | ¥291.3B | ¥134.4B | ¥157.5B | ¥502.5B | Owner earningsOwner earn. |
| — | 22.1% | 17.9% | 13.9% | 22.0% | 17.5% | 19.2% | 8.4% | 8.2% | 23.5% | Owner earnings marginOE mgn |
| — | ¥287.5B | ¥233.4B | ¥180.7B | ¥275.5B | ¥226.7B | ¥291.3B | ¥134.4B | ¥157.5B | ¥502.5B | Free cash flowFCF |
| — | 22.1% | 17.9% | 13.9% | 22.0% | 17.5% | 19.2% | 8.4% | 8.2% | 23.5% | Free cash flow marginFCF mgn |
| ¥70.1B | ¥71.7B | ¥72.1B | ¥73.6B | ¥76.3B | ¥85.6B | ¥100.9B | ¥117.6B | ¥130.3B | ¥137.5B | Dividends paidDiv. paid |
| ¥92.2B | ¥130.7B | ¥160.4B | ¥52.9B | ¥9.2B | ¥50.7B | ¥60.6B | ¥10.7B | ¥7.0B | ¥730M | BuybacksBuybacks |
| 1% | 13% | 14% | 15% | 8% | 9% | 8% | 1% | 2% | 14% | ROICROIC |
| 17% | 13% | 18% | 15% | 9% | 8% | 7% | 1% | 3% | 16% | Return on equityROE |
| 12% | 7% | 12% | 9% | 3% | 3% | −0% | −6% | −5% | 8% | Retained to equityRetained/eq |
| Balance sheet | ||||||||||
| ¥96.8B | ¥331.7B | ¥311.1B | ¥320.4B | ¥326.1B | ¥316.0B | ¥376.8B | ¥335.7B | ¥188.4B | ¥281.6B | Cash & investmentsCash+inv |
| ¥169.6B | ¥25.3B | ¥189.8B | ¥158.6B | ¥149.8B | ¥146.2B | ¥148.7B | ¥194.7B | ¥194.4B | ¥234.1B | ReceivablesReceiv. |
| ¥97.5B | ¥54.0B | ¥55.1B | ¥49.0B | ¥45.9B | ¥28.5B | ¥50.7B | ¥61.4B | ¥75.5B | ¥70.0B | InventoryInvent. |
| ¥267.2B | ¥79.3B | ¥244.9B | ¥207.6B | ¥195.7B | ¥174.7B | ¥199.4B | ¥256.1B | ¥269.9B | ¥304.1B | Operating working capitalOper. WC |
| ¥481.0B | ¥845.6B | ¥857.2B | ¥867.5B | ¥872.6B | ¥923.4B | ¥1.05T | ¥1.19T | ¥1.20T | ¥1.42T | Current assetsCur. assets |
| ¥572.7B | ¥538.7B | ¥650.1B | ¥653.4B | ¥476.5B | ¥505.4B | ¥405.6B | ¥856.5B | ¥626.5B | ¥717.0B | Current liabilitiesCur. liab. |
| 0.8× | 1.6× | 1.3× | 1.3× | 1.8× | 1.8× | 2.6× | 1.4× | 1.9× | 2.0× | Current ratioCurr. ratio |
| — | ¥213.0B | ¥225.9B | ¥278.3B | ¥284.0B | ¥303.0B | ¥328.4B | ¥418.7B | ¥415.2B | ¥441.2B | GoodwillGoodwill |
| ¥1.81T | ¥1.86T | ¥1.90T | ¥2.32T | ¥2.27T | ¥2.33T | ¥2.46T | ¥3.57T | ¥3.34T | ¥3.57T | Total assetsAssets |
| ¥379.7B | ¥367.9B | ¥445.7B | ¥288.0B | ¥317.2B | ¥224.4B | ¥125.0B | ¥920.0B | ¥831.4B | ¥566.0B | Total debtDebt |
| ¥282.9B | ¥36.2B | ¥134.6B | (¥32.4B) | (¥8.9B) | (¥91.6B) | (¥251.8B) | ¥584.3B | ¥643.1B | ¥284.3B | Net debt / (cash)Net debt |
| 11.9× | 119.7× | 354.0× | 109.3× | 64.2× | 67.3× | 41.4× | 3.4× | 2.9× | 37.1× | Interest coverageInt. cov. |
| ¥1.27T | ¥1.27T | ¥1.26T | ¥1.29T | ¥1.39T | ¥1.46T | ¥1.51T | ¥1.60T | ¥1.51T | ¥1.83T | Shareholders’ equityEquity |
| Per share | ||||||||||
| 2.15B | 2.07B | 1.98B | 1.86B | 1.86B | 1.84B | 1.81B | 1.81B | 1.81B | 1.81B | Shares out (diluted)Shares |
| ¥608.99 | ¥628.53 | ¥659.83 | ¥698.71 | ¥671.14 | ¥706.03 | ¥839.17 | ¥886.17 | ¥1056.73 | ¥1182.12 | Revenue / shareRev/sh |
| ¥101.54 | ¥79.60 | ¥112.27 | ¥104.96 | ¥64.77 | ¥67.59 | ¥54.55 | ¥9.42 | ¥28.04 | ¥161.10 | EPS (diluted)EPS |
| — | ¥138.99 | ¥117.91 | ¥97.07 | ¥147.95 | ¥123.49 | ¥160.98 | ¥74.28 | ¥87.04 | ¥277.66 | Owner earnings / shareOE/sh |
| — | ¥138.99 | ¥117.91 | ¥97.07 | ¥147.95 | ¥123.49 | ¥160.98 | ¥74.28 | ¥87.04 | ¥277.66 | Free cash flow / shareFCF/sh |
| ¥32.57 | ¥34.64 | ¥36.42 | ¥39.53 | ¥40.97 | ¥46.62 | ¥55.77 | ¥64.97 | ¥71.98 | ¥75.98 | Dividends / shareDiv/sh |
| — | ¥12.12 | ¥12.72 | ¥22.17 | ¥16.86 | ¥16.74 | ¥20.14 | ¥21.03 | ¥20.45 | ¥31.90 | Cap. spending / shareCapex/sh |
| ¥590.49 | ¥613.05 | ¥635.61 | ¥692.44 | ¥744.51 | ¥795.44 | ¥833.28 | ¥881.93 | ¥836.21 | ¥1010.71 | Book value / shareBVPS |
| 9-yr | 5-yr | |
|---|---|---|
| Revenue / share | +7.6%/yr | +12.0%/yr |
| Owner earnings / share | +9.0%/yr (8-yr) | +13.4%/yr |
| EPS | +5.3%/yr | +20.0%/yr |
| Dividends / share | +9.9%/yr | +13.1%/yr |
| Capital spending / share | +12.9%/yr (8-yr) | +13.6%/yr |
| Book value / share | +6.2%/yr | +6.3%/yr |
Net income is the accountant's number; owner earnings is the cash an owner could take out. The walk between them, off the cash-flow statement, and whether the gap is widening or holding.
In fiscal 2026 the business turned ¥291.5B of profit into ¥502.5B of owner earnings: more cash than the profit line showed, after the non-cash charges and the capital it put back in.
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Reported net income | ¥291.5B | ¥50.7B | ¥17.0B | ¥98.7B | ¥124.1B |
| Working capital & othertiming of cash in and out, other non-cash items | +¥268.7B | +¥143.8B | +¥155.4B | +¥229.1B | +¥133.4B |
| Cash from operations | ¥560.2B | ¥194.5B | ¥172.5B | ¥327.8B | ¥257.4B |
| Capital expenditurecash put back in to keep running and to grow | −¥57.7B | −¥37.0B | −¥38.1B | −¥36.4B | −¥30.7B |
| Owner earnings | ¥502.5B | ¥157.5B | ¥134.4B | ¥291.3B | ¥226.7B |
| Owner-earnings marginowner earnings ÷ revenue | 23% | 8% | 8% | 19% | 17% |
Owner earnings is the cash an owner could pull out without starving the business: operating cash less the capital it must spend to hold its position .
Maintenance capex is estimated as depreciation where a growing business invests above it; free cash flow is the figure the scorecard's free-cash margin reads.
Quality & stewardship
Returns, the balance sheet, and stewardship. The same checks the US pages run, in yen.
Owner’s Scorecard
Will it survive?
- Can it pay its interest? 37.1×ComfortableOperating income ¥382.6B ÷ interest expense ¥10.3B
What this means
Operating profit covers interest with the kind of margin Graham wanted for a defensive holding. Necessary, not sufficient, it says solvent, not cheap.
- How heavy is the debt, net of cash? ¥284.3B · 0.7× operating profitModest net debtCash ¥281.6B − debt ¥566.0B
What this means
Netting ¥281.6B of cash and short-term investments against ¥566.0B of debt leaves ¥284.3B owed, about 0.7× a year's operating profit (1.5× on the gross debt, before the cash). Net debt is the leverage figure that matters: the cash is already set against the debt. Strategic or illiquid investments aren't counted here.
- Not enough data
What this means
The filing data didn't include the inputs for this check.
Is it a good business?
- Solid through the cycle10-yr median, range 1%–15%; 14% latest = NOPAT ¥302.3B ÷ invested capital ¥2.11TIndustry peers: median 21%
What this means
The rate the business earns on the money tied up in it, Buffett's north star, because over time a stock tracks the ROIC beneath it. Above ~15% sustained hints at a moat; a return below the cost of capital (~8%) erodes value as a business grows rather than building it — the test Buffett weighs most. The headline is the median of the last 10 years (it ran 14% most recently), so one peak or trough year doesn't set the verdict. Asset-light businesses (R&D expensed, little capital) read artificially high, pair this with Owner Earnings.
- High through the cycle9-yr median margin, range 8%–23%; latest ¥502.5B = operating cash ¥560.2B − maintenance capex ¥57.7BIndustry peers: median 36%
What this means
What an owner could take out without starving the business: operating cash less the maintenance capital it must spend to hold its position — Buffett's owner earnings. That's 23% of revenue this year, a 18% median across 9 years.
- Cash-backedCash from ops ¥560.2B ÷ net income ¥291.5B
What this means
How much of reported profit showed up as operating cash. Above 1× is reassuring; well below suggests earnings lean on accruals. One year is noisy, growth and working-capital swings distort it, and this is operating cash, not free cash. Watch the multi-year trend.
How is the cash used?
- Reinvests most of itDividends + buybacks ¥138.2B ÷ Owner Earnings ¥502.5B
What this means
Of ¥502.5B Owner Earnings, ¥138.2B (28%) went back to shareholders, ¥137.5B dividends, ¥730M buybacks. Returning most of it is the mark of a mature business with little left to reinvest at a high return; reinvesting most could mean a long runway, or empire-building. The split doesn't say which; the return earned on it (see ROIC) does.
- Investing or harvesting? —Not enough data
What this means
The filing data didn't include the inputs for this check.
Durability & moat, 2017–2026
Whether the record’s returns held, and what the capital reinvested earned.
- Profitable years 10 of 10
What this means
Never lost money over the record, the earnings stability Graham insisted on.
- Return on capital ≥ 15% 1 of 10 yrs
What this means
A moat shows up as a high return on invested capital that holds year after year, not one good vintage.
- Operating margin 12% → 7% (3-yr avg ends)
What this means
The recent-years average (7%) sits below the early years (12%), but the latest year (18%) is back near the early level: a cyclical trough dragging the window down, not a one-way slide. The through-cycle median is 11% — read it across the cycle, not on the dip.
- Reinvestment, incremental ROIC −1%
What this means
Reinvested capital came back at a negative incremental return over this window — the invested base grew while operating profit did not. The filings show where it went.
- Owner earnings growth +3%/yr
What this means
Owner earnings grew about 3% a year over the record.
- Worst year 2017 · 1.2% op. margin
What this means
Stayed profitable even in its hardest year, the resilience that survives recessions.
- Share count −1.9%/yr
What this means
The share count is shrinking, buybacks are quietly growing your slice of the business.
- Dividend record rising
What this means
Paid and raised the dividend across the record, the continuity Graham prized.
All figures as filed; the source filing is linked above.
How the cash was used, 2018–2026
Over the record, the business generated ¥2.61T of operating cash; how management split it reads as a balanced allocator, splitting cash between the business, owners, and the balance sheet.
- Reinvested¥322.9B · 12%
- Dividends¥865.5B · 33%
- Buybacks¥482.9B · 18%
- Retained (debt / cash)¥941.2B · 36%
- Returned to owners¥1.35T
59% of the owner earnings the business produced over the span, ¥865.5B as dividends and ¥482.9B as buybacks.
- Average price paid for buybacks—
Buybacks ran ¥482.9B over the span, but the filings don't tag the share count needed to deduce the average price paid.
- Net change in share count−12.5%
The diluted count fell from 2069M to 1810M, so the buybacks outran the stock issued to staff.
- Dividend record¥75.98/sh
Paid in 9 of the years on record, the per-share dividend growing about 10% a year. It was never cut over the span.
Buybacks are gross of stock issued to staff; the share-count line above is the net of that, the figure that decides whether owners gained. The average price paid blends a year of purchases (and any accelerated repurchase), so it is close, not exact. The record of where the cash went and on what terms.
Inverting the record
Invert: instead of why Astellas Pharma is a good business, the question is what would make owning it a mistake, and whether those marks are in the record. Disconfirming tests across 2017–2026.
1 of the 5 tests turned up something to look into; the other 4 came back clean.
- Look hereDid debt outgrow the business?¥379.7B → ¥566.0B
Debt rose from ¥379.7B to ¥566.0B while owner earnings went from about ¥233.9B to ¥264.8B — about 1.6 years of owner earnings in debt then, about 2.1 now: measured against what the business earns, the balance sheet carries more debt than it did. Debt raised for buybacks or deals rather than growth is the kind that bites in a downturn.
- Is it less profitable than it was?
- Did the share count rise anyway?
- Did reported profit become cash?
- Did receivables and inventory outpace sales?
Each test is read from the filings and is noisy alone; a flag can mark a cyclical trough or a year of heavy investment as easily as a problem. The filing says which.
The price
What a price would have to assume, set against the record above.
What the price implies
reverse-DCFType today's close and see the owner-earnings growth you'd have to believe to justify it, beside what Astellas Pharma has delivered.
Astellas Pharma’s latest year runs above its own through-cycle margin — the reported figure may flatter a peak. So the tool opens on the through-cycle base, Graham’s averaging cutting both ways; clear the toggle below to read the latest year exactly as reported.
Through the cycle, Astellas Pharma earns about ¥382.3B on its 17.9% median owner-earnings margin. This year’s 23.5% margin runs above that; the reported figure may flatter a peak you'd be paying on. Normalize, below, values the price on that through-cycle figure rather than the latest year. It comes pre-checked here for that reason, the same rule that already normalizes a trough; clear it to price the year as filed.
—
9.0% = the 4.55% 10-year Treasury (Jul 15, 2026) + 4.45 points of equity premium. The rate you require is yours to set.
Enter a price above to run it.
A dated snapshot of the price you typed, the assumptions you set, and what the page showed for them. A snapshot is never edited after it is saved. Your notebook is yours alone — the commitment states what is stored and what we will never do.
Graham capped the multiple at 15×; Buffett and Munger let that rule go: a wonderful business can deserve 50× if the thesis holds. The gate marks the bargain-hunter's floor.
Prefilled with the 10-year Treasury (4.55%, as of Jul 15, 2026). Edit it for today’s exact figure, or a AAA corporate yield.
Graham measured a stock against the bond you could own instead, the heart of his margin of safety. Enter a price above to weigh the owner-earnings yield against this bond.
Owner earnings ¥502.5B on 1810M diluted shares; net debt ¥284.3B. The base opens on the through-cycle figure (the latest year sits above the record’s own median, and Graham’s averaging cuts both ways); clear Normalize to use the year as filed. Net of stock comp treats option pay as the expense it is. The dials set the multiple a growth belief justifies; the price, and every dollar on this page, is yours.
Figures from EDINET, the Financial Services Agency’s disclosure system, the same kind of filing the US pages draw from EDGAR. A separate pool: these names never pass through the US industry classifier.
Manual order: ← 4502 its page in the Manual 4506 →
Industry order: ← 4502 the Pharmaceuticals chapter 4506 →